Table 1.
QALY and productivity losses associated with additional excess cancer deaths by cancer site.
| Cancer site | Approach | Pre-pandemic (observed) | First wave pandemic (estimated with 95% CI) | Differences in observed and estimated QALY and productivity losses due to additional excess cancer deaths |
|---|---|---|---|---|
| Breast | Deaths | 3564 | 3908 (3891–3926) | 344 (326–361) |
| QALYs (thousands) | 37.1 | 41.3 (40.1–41.6) | 4.1 (3.9–4.4) | |
| Productivity losses (GBP million) | ||||
| Human capital approach | 267.0 | 290.2 (285.2–295.6) | 23.2 (18.2–28.6) | |
| Colorectal | Deaths | 9416 | 11,062 (10,982–11,145) | 1646 (1566–1729) |
| QALYs (thousands) | 80.9 | 95.9 (95.0–96.8) | 15.0 (14.1–16.0) | |
| Productivity losses (GBP million) | ||||
| Human capital approach | 410.1 | 445.8 (432.6–458.8) | 35.7 (22.4–48.7) | |
| Lung | Deaths | 25,800 | 27,090 (27,081–27,099) | 1290 (1281–1299) |
| QALYs (thousands) | 220.1 | 231.0 (230.1–231.8) | 10.9 (9.9–11.7) | |
| Productivity losses (GBP million) | ||||
| Human capital approach | 805.3 | 843.6 (819.3–865.2) | 38.3 (14.0–59.9) | |
| Oesophagus | Deaths | 5713 | 6048 (6038–6047) | 335 (325–345) |
| QALYs (thousands) | 50.5 | 53.2 (52.8–53.7) | 2.7 (2.3–3.1) | |
| Productivity losses (GBP million) | ||||
| Human capital approach | 195.5 | 202.1 (191.4–213.1) | 6.6 (−4.0–17.6) | |
| Total cancer | Deaths | 44,493 | 48,109 (48,020–48,200) | 3615 (3526–3706) |
| QALYs (thousands) | 388.7 | 421.4 (419.9–422.8) | 32.7 (31.3–34.1) | |
| Productivity losses (GBP million) | ||||
| Human capital approach | 1677.9 | 1781.7 (1751.1–-1810.1) | 103.8 (73.2–132.2) |
Abbreviations: QALY – quality-adjusted life-years discounted to 2019 value.
Notes: 95% confidence intervals obtained from 500 bootstraps, percentile method. Totals may not add up due to rounding.